TITLE

IMS HEALTH SIGNS WYETH LEDERLE PORTUGAL FOR PRM

PUB. DATE
June 2000
SOURCE
Worldwide Biotech;Jun2000, Vol. 12 Issue 6, p1
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
Reports that the IMS Health company's Strategic Technologies unit will implement leading-edge Pharmaceutical Relationship Management solutions for Wyeth Lederle Portugal.
ACCESSION #
3229258

 

Related Articles

  • More help for depression.  // Cortlandt Forum;Jul/Aug2008, Vol. 21 Issue 7, p11 

    The article evaluates the Pristiq Antidepressant from Wyeth.

  • Wyeth's Rapamune gets black box warning. Dickinson, James G. // Medical Marketing & Media;Jun2002, Vol. 37 Issue 6, p28 

    Reports on the warning label for Rapamune from Wyeth. Information on the risk of hepatic artery thrombosis; Occurrence of death in de novo liver transplantation; Combination of cyclosporine and tacrolimus.

  • Zone in on: Manufacturing. Greb, Erik // Pharmaceutical Technology;Mar2010, Vol. 34 Issue 3, p20 

    The article focuses on the updated pipeline of Pfizer Inc. after its acquisition of Wyeth in the U.S.

  • Wyeth reports off-label use of venlafaxine associated with pediatric risks.  // Formulary;Oct2003, Vol. 38 Issue 10, p575 

    Reports on the potential risks associated with Wyeth's antidepressant venlafaxine when the drug is administered in the pediatric population. Finding that the efficacy of venlafaxine was not established in pediatric patients for major depressive disorder or generalized anxiety disorder; Need for...

  • Fear of Deepening Woes. Quinn, William T. // njbiz;10/28/2002, Vol. 15 Issue 44, p28 

    Focuses on the finances of pharmaceutical company Wyeth for the third quarter of 2002. Earnings of the company; Price of the company's stocks; Analysis of the drop in Wyeth's profit margin; Share of the Premarin line of hormone replacement products in the company's sales.

  • Wyeth leaves impression on Pfizer quarterly report. Daks, Martin C. // njbiz;5/10/2010, Vol. 23 Issue 19, p2 

    The article reports on the first quarter financial report of Pfizer Inc. for 2010 following its acquisition of Wyeth.

  • Mims: UPDATE.  // GP: General Practitioner;2/24/2003, p70 

    Presents information about developments in the Monthly Index of Medical Specialties as of February 24, 2003. Launch of ZotonFasTab by Wyeth Inc.; Indications for the use of the tablets; Capsules for the treatment of bulimia nervosa and obsessive compulsive disorder launched by Generics Ltd.

  • Rotavirus vaccine withdrawn. Maudlin, Robert K. // Modern Medicine;Dec99, Vol. 67 Issue 12, p55 

    Reports on the withdrawal of RotaShield rotavirus vaccine by Wyeth Lederle Vaccines company from the market because of the drug's possible association with the development of intussusception. Postponement of the drug's administration.

  • MultiRoute, MultiSystems enhance Wyeth's philosophy of innovation. Cardenas, Felipe // Caribbean Business;7/17/2003, Vol. 31 Issue 28, p33 

    Reports on the use of personal digital assistant technology by the sales team at Wyeth in Puerto Rico. Competitiveness in the pharmaceutical sector; Increase in industrial productivity; Options for real-time wireless communication.

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics